TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Impact of Care Pathways on Interprofessional Teamwork: an International Cluster Randomized Controlled Trial
Brief Summary: Care pathways are complex interventions to support the interprofessional team in the redesign of their care process. This international cluster randomised trial will analyse the impact of the development and implementation of care pathways on the interprofessional teamwork.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Home based pulmonary rehabilitation with exercise | Arm Label: exercise; Type: ACTIVE_COMPARATOR; Interventions: Other: Home based pulmonary rehabilitation with exercise | Intervention Type: OTHER; Name: Home based pulmonary rehabilitation with exercise; Assigned to Arm(s): Placebo, exercise
B: Arm Label: Care pathway teams.; Type: EXPERIMENTAL; Interventions: Behavioral: Care pathway. | Arm Label: Usual care teams.; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Care pathway.; Assigned to Arm(s): Care pathway teams.
C: Arm Label: Tool + Self-management Support Program; Type: EXPERIMENTAL; Interventions: Device: Tool, Behavioral: Self-management Support Program | Arm Label: Self- management Support Program; Type: EXPERIMENTAL; Interventions: Behavioral: Self-management Support Program | Arm Label: Care as usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Tool; Assigned to Arm(s): Tool + Self-management Support Program | Intervention Type: BEHAVIORAL; Name: Self-management Support Program; Assigned to Arm(s): Self- management Support Program, Tool + Self-management Support Program
D: Arm Label: Lifestyle counselling; Type: EXPERIMENTAL; Interventions: Other: Disease management program | Arm Label: Comparator; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual care | Intervention Type: OTHER; Name: Disease management program; Assigned to Arm(s): Lifestyle counselling | Intervention Type: BEHAVIORAL; Name: Usual care; Assigned to Arm(s): Comparator

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Double-blind, Placebo-controlled (With Rescue Medication), Multi-centre Study to Evaluate the Efficacy and Safety of Inhaled Fluticasone Furoate in the Treatment of Persistent Asthma in Adults and Adolescents Not Currently Receiving Inhaled Corticosteroids
Brief Summary: A randomised, double-blind, placebo-controlled (with rescue medication), multi-centre study to evaluate the efficacy and safety of inhaled fluticasone furoate in the treatment of persistent asthma in adults and adolescents not currently receiving inhaled corticosteroids


Options:
A: Arm Label: Fluticasone furoate 50mcg; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone furoate 50mcg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Fluticasone furoate 50mcg; Assigned to Arm(s): Fluticasone furoate 50mcg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: GW685698X 200mcg,GW685698X 200mcg and 400mcg | Intervention Type: DRUG; Name: GW685698X 200mcg,GW685698X 200mcg and 400mcg; Assigned to Arm(s): Arm 1
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: budesonide/formoterol (Symbicort) | Intervention Type: DRUG; Name: budesonide/formoterol (Symbicort); Assigned to Arm(s): 1
D: Arm Label: MF/F MDI 200/10 mcg BID; Type: EXPERIMENTAL; Interventions: Drug: Mometasone furoate/formoterol (MF/F) MDI | Arm Label: F/SC DPI 250/50 mcg BID; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone propionate/salmeterol (F/SC) DPI | Intervention Type: DRUG; Name: Mometasone furoate/formoterol (MF/F) MDI; Assigned to Arm(s): MF/F MDI 200/10 mcg BID | Intervention Type: DRUG; Name: Fluticasone propionate/salmeterol (F/SC) DPI; Assigned to Arm(s): F/SC DPI 250/50 mcg BID

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Double-Blind, Randomized, Placebo-Controlled Phase 2 Safety and Efficacy Trial of MultiStem® in Adults With Ischemic Stroke
Brief Summary: A study to examine the safety and potential effectiveness of the adult stem cell investigational product, MultiStem, in adults who have suffered an ischemic stroke. The hypothesis is that MultiStem will be safe and provide benefit following an ischemic stroke.


Options:
A: Arm Label: CTX0E03 DP; Type: EXPERIMENTAL; Interventions: Biological: CTX0E03 neural stem cells | Intervention Type: BIOLOGICAL; Name: CTX0E03 neural stem cells; Assigned to Arm(s): CTX0E03 DP
B: Arm Label: SB623 Implant (2.5M); Type: EXPERIMENTAL; Interventions: Biological: SB623 | Arm Label: SB623 Implant (5.0M); Type: EXPERIMENTAL; Interventions: Biological: SB623 | Arm Label: SB623 Implant (10.0M); Type: EXPERIMENTAL; Interventions: Biological: SB623 | Intervention Type: BIOLOGICAL; Name: SB623; Assigned to Arm(s): SB623 Implant (10.0M), SB623 Implant (2.5M), SB623 Implant (5.0M)
C: Arm Label: bone marrow stem cells; Type: OTHER; Interventions: Procedure: Infusion on autologous CD34+ stem cells into middle cerebral artery | Intervention Type: PROCEDURE; Name: Infusion on autologous CD34+ stem cells into middle cerebral artery; Assigned to Arm(s): bone marrow stem cells
D: Arm Label: Cohort 1; Type: EXPERIMENTAL; Interventions: Biological: MultiStem, Biological: Placebo | Arm Label: Cohort 2; Type: EXPERIMENTAL; Interventions: Biological: MultiStem, Biological: Placebo | Arm Label: Cohort 3; Type: EXPERIMENTAL; Interventions: Biological: MultiStem, Biological: Placebo | Intervention Type: BIOLOGICAL; Name: MultiStem; Assigned to Arm(s): Cohort 1, Cohort 2, Cohort 3 | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Cohort 1, Cohort 2, Cohort 3

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of Selective Vitamin D Receptor Activation With Paricalcitol for Reduction of Proteinuria in Kidney Transplant Recipients: a Randomized Controlled Trial
Brief Summary: The study 'Safety and Efficacy of Paricalcitol for Reduction of Proteinuria in Kidney Transplant Recipients' is designed to assess the effects of paricalcitol in kidney transplant recipients with proteinuria.

It is a single centre, randomized, placebo-controlled, double-blind clinical trial that tests the hypothesis that 24 weeks' treatment with paricalcitol compared to placebo will result in a decrease in urinary protein excretion in recipients of a kidney transplant at least three months after transplantation. Additionally, the effects of paricalcitol on albuminuria, estimated glomerular filtration rate, and blood pressure will be investigated.


Options:
A: Intervention Type: DRUG; Name: Cinacalcet HCl; Assigned to Arm(s): N/A
B: Arm Label: Paricalcitol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paricalcitol | Arm Label: Matching placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Paricalcitol; Assigned to Arm(s): Paricalcitol | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Matching placebo
C: Arm Label: Cholecalciferol 100 000 UI; Type: EXPERIMENTAL; Interventions: Drug: Cholecalciferol 100 000 UI | Arm Label: Cholecalciferol 12 000 UI (Control); Type: ACTIVE_COMPARATOR; Interventions: Drug: Cholecalciferol 12 000 UI | Intervention Type: DRUG; Name: Cholecalciferol 100 000 UI; Assigned to Arm(s): Cholecalciferol 100 000 UI | Intervention Type: DRUG; Name: Cholecalciferol 12 000 UI; Assigned to Arm(s): Cholecalciferol 12 000 UI (Control)
D: Arm Label: Denosumab; Type: EXPERIMENTAL; Interventions: Drug: Denosumab (Prolia) | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Denosumab (Prolia); Assigned to Arm(s): Denosumab

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Exercise on Disease Activity and Cardiovascular Risk Factors in Patients With AS: A Single Blind Randomized Controlled Trail
Brief Summary: Background:

Exercise is recommended as a cornerstone in the treatment of ankylosing spondylitis together with medication. Last years, increased risk of cardiovascular diseases in patient with inflammatory diseases is reported, probably caused by inflammation and increased prevalence of traditional risk factors. In both healthy adults and other patient groups, cardiorespiratory and muscular strength exercises have been shown to have a positive effect on inflammation as well as on cardiovascular risk factors. To our knowledge this has not been shown in patients with ankylosing spondylitis.

Objective: The aim of this study is to investigate the effects of a cardiorespiratory and muscular strength exercise program on disease activity and cardiovascular risk factors in patients with ankylosing spondylitis


Options:
A: Arm Label: Exercise Group; Type: EXPERIMENTAL; Interventions: Other: Exercise | Arm Label: Control Group; Type: OTHER; Interventions: Other: Drug treatment | Intervention Type: OTHER; Name: Exercise; Assigned to Arm(s): Exercise Group | Intervention Type: OTHER; Name: Drug treatment; Assigned to Arm(s): Control Group
B: Arm Label: Back pain / peripheral arthritis; Type: N/A; Interventions: N/A
C: Arm Label: Training; Type: EXPERIMENTAL; Interventions: Behavioral: Cardiovascular Training | Intervention Type: BEHAVIORAL; Name: Cardiovascular Training; Assigned to Arm(s): Training
D: Arm Label: Exercise group; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Exercise group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2, Randomized, Controlled, Observer Blind, Single Center Study of the Safety, Reactogenicity and Immunogenicity of the NVGH Glycoconjugate Vaccine Against S. Typhi in Children, Older Infants and Infants
Brief Summary: This phase 2 trial is aimed to obtain information on the safety and immunogenicity of the Vi-CRM197 in children and infants from various age groups in the Philippines where Typhoid Fever is highly endemic and an efficacious vaccine against this disease is very much needed.


Options:
A: Arm Label: Vi-TCV; Type: EXPERIMENTAL; Interventions: Biological: Vi-TCV | Arm Label: Vi-PS Vaccine; Type: ACTIVE_COMPARATOR; Interventions: Biological: Vi-PS Vaccine | Arm Label: Control (Men ACWY); Type: OTHER; Interventions: Biological: Control (Men ACWY) | Intervention Type: BIOLOGICAL; Name: Vi-TCV; Assigned to Arm(s): Vi-TCV | Intervention Type: BIOLOGICAL; Name: Vi-PS Vaccine; Assigned to Arm(s): Vi-PS Vaccine | Intervention Type: BIOLOGICAL; Name: Control (Men ACWY); Assigned to Arm(s): Control (Men ACWY)
B: Arm Label: M01ZH09 vaccine; Type: EXPERIMENTAL; Interventions: Biological: M10ZH09 vaccine | Arm Label: Vaccine placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Vaccine placebo (excipients only) | Arm Label: Ty21a vaccine; Type: OTHER; Interventions: Biological: Ty21a | Intervention Type: BIOLOGICAL; Name: Vaccine placebo (excipients only); Assigned to Arm(s): Vaccine placebo | Intervention Type: BIOLOGICAL; Name: Ty21a; Assigned to Arm(s): Ty21a vaccine | Intervention Type: BIOLOGICAL; Name: M10ZH09 vaccine; Assigned to Arm(s): M01ZH09 vaccine
C: Arm Label: Vi-CRM, Older infants; Type: EXPERIMENTAL; Interventions: Biological: Vi-CRM197 vaccine | Arm Label: PNC13, Older infants; Type: ACTIVE_COMPARATOR; Interventions: Biological: Pneumococcal conjugate vaccine | Arm Label: Vi-CRM, Infants; Type: EXPERIMENTAL; Interventions: Biological: Vi-CRM197 vaccine | Arm Label: PNC13, Infants; Type: ACTIVE_COMPARATOR; Interventions: Biological: Pneumococcal conjugate vaccine | Arm Label: Vi-CRM, Children; Type: EXPERIMENTAL; Interventions: Biological: Vi-CRM197 vaccine | Arm Label: Vi-PS, Children; Type: ACTIVE_COMPARATOR; Interventions: Biological: Pneumococcal conjugate vaccine, Biological: Vi Polysaccharide (PS) vaccine | Intervention Type: BIOLOGICAL; Name: Vi-CRM197 vaccine; Assigned to Arm(s): Vi-CRM, Children, Vi-CRM, Infants, Vi-CRM, Older infants | Intervention Type: BIOLOGICAL; Name: Pneumococcal conjugate vaccine; Assigned to Arm(s): PNC13, Infants, PNC13, Older infants, Vi-PS, Children | Intervention Type: BIOLOGICAL; Name: Vi Polysaccharide (PS) vaccine; Assigned to Arm(s): Vi-PS, Children
D: Arm Label: NVGH Vi-CRM197 conjugate vaccine; Type: EXPERIMENTAL; Interventions: Biological: NVGH Vi-CRM197 | Arm Label: Vi-polysaccharide vaccine; Type: ACTIVE_COMPARATOR; Interventions: Biological: Typherix | Intervention Type: BIOLOGICAL; Name: Typherix; Assigned to Arm(s): Vi-polysaccharide vaccine | Intervention Type: BIOLOGICAL; Name: NVGH Vi-CRM197; Assigned to Arm(s): NVGH Vi-CRM197 conjugate vaccine

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Long-Term, Randomized, Study of the Safety and Tolerability of a Fixed-Dose Combination of Aclidinium Bromide/Formoterol Fumarate Compared With Formoterol Fumarate in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)
Brief Summary: The purpose of this study is to assess the long-term safety and tolerability of inhaled aclidinium bromide/formoterol in patients with moderate to severe, stable chronic obstructive pulmonary disease (COPD).


Options:
A: Arm Label: COPD subjects; Type: N/A; Interventions: Other: Novel endpoint determination | Arm Label: Smoker controls; Type: N/A; Interventions: Other: Novel endpoint determination | Arm Label: Non-smoker controls; Type: N/A; Interventions: Other: Novel endpoint determination | Intervention Type: OTHER; Name: Novel endpoint determination; Assigned to Arm(s): COPD subjects, Non-smoker controls, Smoker controls
B: Arm Label: Aclidinium Bromide/Formoterol Fumarate FDC 400/12μg; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium/Formoterol | Arm Label: Placebo to Aclidinium/Formoterol; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aclidinium/Formoterol; Assigned to Arm(s): Aclidinium Bromide/Formoterol Fumarate FDC 400/12μg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo to Aclidinium/Formoterol
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium Bromide/Formoterol Fumarate | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Formoterol Fumarate | Intervention Type: DRUG; Name: Aclidinium Bromide/Formoterol Fumarate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Formoterol Fumarate; Assigned to Arm(s): 2
D: Arm Label: Aclidinium Bromide / Formoterol Fumarate; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium Bromide / Formoterol Fumarate | Arm Label: Salmeterol / Fluticasone propionate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Salmeterol / Fluticasone | Intervention Type: DRUG; Name: Aclidinium Bromide / Formoterol Fumarate; Assigned to Arm(s): Aclidinium Bromide / Formoterol Fumarate | Intervention Type: DRUG; Name: Salmeterol / Fluticasone; Assigned to Arm(s): Salmeterol / Fluticasone propionate

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Long-Term, Randomized, Study of the Safety and Tolerability of a Fixed-Dose Combination of Aclidinium Bromide/Formoterol Fumarate Compared With Formoterol Fumarate in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)
Brief Summary: The purpose of this study is to assess the long-term safety and tolerability of inhaled aclidinium bromide/formoterol in patients with moderate to severe, stable chronic obstructive pulmonary disease (COPD).


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium Bromide/Formoterol Fumarate | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Formoterol Fumarate | Intervention Type: DRUG; Name: Aclidinium Bromide/Formoterol Fumarate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Formoterol Fumarate; Assigned to Arm(s): 2
B: Arm Label: QVA149; Type: EXPERIMENTAL; Interventions: Drug: QVA149 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: QVA149; Assigned to Arm(s): QVA149 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: Test: Tiotropium 18 µg per day (one inhalation capsule) plus 12 µg formoterol twice daily (two times one inhalation capsule); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Reference: Salmeterol MDI 50 µg (2 puffs of 25 µg each) b.i.d., plus fluticasone propionate MDI 500 µg (2 puffs of 250 µg each) b.i.d.; Assigned to Arm(s): N/A
D: Arm Label: Fluticasone Furoate / GW642444 (vilanterol); Type: EXPERIMENTAL; Interventions: Drug: Fluticasone Furoate 100mcg / GW642444 (vilanterol) 25mcg | Arm Label: Fluticasone Propionate / salmeterol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone Propionate 250mcg/ salmeterol 50mcg | Intervention Type: DRUG; Name: Fluticasone Furoate 100mcg / GW642444 (vilanterol) 25mcg; Assigned to Arm(s): Fluticasone Furoate / GW642444 (vilanterol) | Intervention Type: DRUG; Name: Fluticasone Propionate 250mcg/ salmeterol 50mcg; Assigned to Arm(s): Fluticasone Propionate / salmeterol

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Controlled Trial for Efficacy of Botulinum Toxin Type A in Treatment of Patients Suffering Bladder Pain Syndrome/Interstitial Cystitis With Hunners' Lesions
Brief Summary: The etiology of bladder pain syndrome is unknown. Therefore the management is directed to pain relief, as bladder pain is believed to drive both voiding frequency and nocturia. Botulinum toxin A has been shown to decrease noxious input. Several studies showed efficacy of botox for treatment of painful bladder.

The aim of this study is to evaluate the efficacy of Botulinum toxin in patients who are suffering bladder pain syndrome with Hunner lesions during cystoscopy.


Options:
A: Arm Label: Bladder instillation WITH triamcinolone acetonide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bladder instillation WITH triamcinolone acetonide | Arm Label: Bladder instillation WITHOUT triamcinolone acetonide; Type: PLACEBO_COMPARATOR; Interventions: Drug: Bladder instillation WITHOUT triamcinolone acetonide | Intervention Type: DRUG; Name: Bladder instillation WITH triamcinolone acetonide; Assigned to Arm(s): Bladder instillation WITH triamcinolone acetonide | Intervention Type: DRUG; Name: Bladder instillation WITHOUT triamcinolone acetonide; Assigned to Arm(s): Bladder instillation WITHOUT triamcinolone acetonide
B: Arm Label: Botulinum toxin; Type: ACTIVE_COMPARATOR; Interventions: Procedure: intratrigonal injection of botulinum toxin | Arm Label: cystoscopy with hydrodistension; Type: SHAM_COMPARATOR; Interventions: Procedure: cystoscopy | Intervention Type: PROCEDURE; Name: intratrigonal injection of botulinum toxin; Assigned to Arm(s): Botulinum toxin | Intervention Type: PROCEDURE; Name: cystoscopy; Assigned to Arm(s): cystoscopy with hydrodistension
C: Arm Label: Post Tibial Nerve Stimulation Group (PTNS); Type: EXPERIMENTAL; Interventions: Device: NURO TM | Arm Label: Sham Group; Type: SHAM_COMPARATOR; Interventions: Device: Sham | Intervention Type: DEVICE; Name: NURO TM; Assigned to Arm(s): Post Tibial Nerve Stimulation Group (PTNS) | Intervention Type: DEVICE; Name: Sham; Assigned to Arm(s): Sham Group
D: Arm Label: JNJ-42160443; Type: EXPERIMENTAL; Interventions: Drug: JNJ-42160443 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: JNJ-42160443; Assigned to Arm(s): JNJ-42160443

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Enhancement of Co-regulation Between Mother and Infant Via Family Nurture Intervention (FNI) in the NICU: Short and Long Term Effects on Development
Brief Summary: The purpose of this study is to test the efficacy of a family nurture intervention in the neonatal intensive care unit (NICU). Infants receiving enhanced mother-infant and family nurture are compared to infants receiving standard NICU care. The intervention enhances mother/infant interactions that are vital to early development in the infant. The main goal is to get the mother and infant into biological synchrony, emotional attunement and mutual calm through an activity referred to as a "calming cycle". Mother's are encouraged to engage in the calming cycle activities as much as possible. Her increased effectiveness in calming her infant is hypothesized to improve the mother's view of her baby, reduce negative emotions about having delivered a baby prematurely, and help her gain confidence in her care-taking abilities, which in other studies predicted shorter length of stay and fewer re-hospitalizations. Another goal is to assist mothers in repeating the calming cycle activities providing appropriate types of stimulation for their babies that are important for social, emotional, and neurobehavioral development. Since preterm babies are often easily upset, mothers will be taught how to comfort and calm their babies. Assessments in the NICU and in follow-up visits for two years will test the immediate and long-term effects of this new approach to the nurture of prematurely born infants.


Options:
A: Arm Label: Phase 1: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Phase 1: Facilitated infant care; Type: EXPERIMENTAL; Interventions: Behavioral: Family Nurture Intervention | Arm Label: Phase 2: Effectiveness; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Family Nurture Intervention | Intervention Type: BEHAVIORAL; Name: Family Nurture Intervention; Assigned to Arm(s): Phase 1: Facilitated infant care, Phase 2: Effectiveness
B: Arm Label: Individually customized physiotherapy; Type: OTHER; Interventions: Other: Individually customized physiotherapy | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Individually customized physiotherapy; Assigned to Arm(s): Individually customized physiotherapy
C: Intervention Type: BEHAVIORAL; Name: Sensitizing parents; Assigned to Arm(s): N/A
D: Arm Label: Crawli Group; Type: EXPERIMENTAL; Interventions: Behavioral: Crawling stimulation with the crawliskate | Arm Label: Mattress Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Tummy time without the crawliskate | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Crawling stimulation with the crawliskate; Assigned to Arm(s): Crawli Group | Intervention Type: BEHAVIORAL; Name: Tummy time without the crawliskate; Assigned to Arm(s): Mattress Group

Answer: A